ARROWHEAD PHARMACEUTICALS, INC. (ARWR)

57.23 0.98 (1.74%)

As of 2025-12-02 08:31:20 EST

Arrowhead Pharmaceuticals, Inc. is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead's products in development act through RNA interference (RNAi) mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease.

Traded asNasdaq: ARWR
ISINUS04280A1007
CIK0000879407
LEI549300O3CSB8T7OZ3D66
EIN460408024
SectorBiotechnology
IndustryPharmaceutical Preparations
CEOChristopher Anzalone, Ph.D.
Employees609
Fiscal Year End0930
Address177 E COLORADO BLVD, PASADENA, CA, 91105
Phone626-696-4702
Websitehttp://arrowheadpharma.com
Stock Quotes
trading_symbolregistrant_nametimepricechangepercentage_change
ARWRARROWHEAD PHARMACEUTICALS, INC.2025-12-02 08:31:2057.230.981.74
This is a preview of the latest data. Subscribe to access the full data.
Company Information
trading_symbolcentral_index_keyregistrant_nameisin_numberlei_numberein_numberexchangesic_codesic_descriptionfiscal_year_endstate_of_incorporationaddress_streetaddress_cityaddress_stateaddress_zip_codeaddress_countryaddress_country_codephone_numbermailing_addressbusiness_addressformer_nameindustryfounding_datechief_executive_officernumber_of_employeeswebsitemarket_capshares_issuedshares_outstandingdescriptionupdate_time
ARWR0000879407ARROWHEAD PHARMACEUTICALS, INC.US04280A1007549300O3CSB8T7OZ3D66460408024Nasdaq2834Pharmaceutical Preparations0930DE177 E COLORADO BLVDPASADENACA91105UNITED STATESUS626-696-4702177 E COLORADO BLVD, PASADENA, CA, 91105177 E COLORADO BLVD, PASADENA, CA, 91105ARROWHEAD RESEARCH CORPBiotechnology2004-01-01Christopher Anzalone, Ph.D.609http://arrowheadpharma.com1,400,000,000135,702,000135,809,558Arrowhead Pharmaceuticals, Inc. is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead's products in development act through RNA interference (RNAi) mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease.2025-11-27 15:52:12
This is a preview of the latest data. Subscribe to access the full data.
ARWR Stock Price (End-of-Day)
This is a preview of the latest data. Subscribe to access the full data.
ARWR Stock Price (1-Minute)
This is a preview of the latest data. Subscribe to access the full data.
Market Cap
Fiscal YearMarket CapChange In Market CapPercentage Change In Market CapShares OutstandingChange In Shares OutstandingPercentage Change In Shares Outstanding
20251,400,000,000-1,600,000,000-53.3333135,809,55811,375,1169.1415
20243,000,000,000700,000,00030.4348124,434,44217,002,23215.826
20232,300,000,000-1,800,000,000-43.9024107,432,2101,426,4881.3457
This is a preview of the latest data. Subscribe to access the full data.
Executive Compensation
Executive NameExecutive PositionFiscal YearSalaryBonusStock AwardsIncentive Plan CompensationOther CompensationTotal Compensation
Javier San MartinChief Medical Officer2024260,52902,589,7500606,2853,456,564
Christopher AnzaloneChief Executive Officer, President2024951,012010,319,0001,152,0001,46112,423,473
Kenneth MyszkowskiChief Financial Officer2024592,36902,589,750314,49615,7613,512,376
Patrick O’BrienChief Operating Officer, General Counsel2024605,25902,935,050378,00015,2613,933,570
Tracie OliverChief Commercial Officer2024484,06502,589,75002,9653,076,780
This is a preview of the latest data. Subscribe to access the full data.
Employee Count
Fiscal YearEmployee Count
2025711
2024609
2023525
This is a preview of the latest data. Subscribe to access the full data.
Income Statements
Fiscal Year202520242023
Revenue829,448,000—240,735,000
Cost Of Revenue———
Gross Profit———
Research And Development Expenses607,159,000—353,188,000
General And Administrative Expenses123,943,000—92,549,000
Operating Expenses731,102,000—445,737,000
Operating Income98,346,000—-205,002,000
Net Income-1,631,000—-205,275,000
Earnings Per Share Basic-0.01—-1.92
Earnings Per Share Diluted-0.01—-1.92
Weighted Average Shares Outstanding Basic133,758,000—106,750,000
Weighted Average Shares Outstanding Diluted133,758,000—106,750,000
This is a preview of the latest data. Subscribe to access the full data.
Balance Sheet Statements
Fiscal Year202520242023
Cash And Cash Equivalents226,548,000—110,891,000
Marketable Securities Current692,818,000—0
Accounts Receivable6,824,000—0
Inventories———
Non Trade Receivables———
Other Assets Current13,516,000—7,082,000
Total Assets Current950,639,000—419,521,000
Marketable Securities Non Current468,490,000—0
Property Plant And Equipment382,515,000—290,262,000
Other Assets Non Current1,389,000—210,000
Total Assets Non Current434,656,000—346,031,000
Total Assets1,385,295,000—765,552,000
Accounts Payable17,674,000—35,866,000
Deferred Revenue2,399,000—866,000
Short Term Debt40,000,000——
Other Liabilities Current10,811,000—435,000
Total Liabilities Current195,487,000—105,456,000
Long Term Debt214,883,000——
Other Liabilities Non Current———
Total Liabilities Non Current686,392,000—372,934,000
Total Liabilities881,879,000—478,390,000
Common Stock231,000—200,000
Retained Earnings-1,627,154,000—-1,026,030,000
Accumulated Other Comprehensive Income6,443,000—-3,222,000
Total Shareholders Equity466,052,000—271,343,000
This is a preview of the latest data. Subscribe to access the full data.
Cash Flow Statements
Fiscal Year202520242023
Depreciation And Amortization23,928,000—12,493,000
Share Based Compensation Expense63,366,000—78,130,000
Other Non Cash Income Expense———
Change In Accounts Receivable56,967,000—-1,410,000
Change In Inventories———
Change In Non Trade Receivables———
Change In Other Assets———
Change In Accounts Payable6,286,000—32,998,000
Change In Other Liabilities-3,094,000—0
Cash From Operating Activities179,552,000—-153,890,000
Purchases Of Marketable Securities796,258,000—246,141,000
Sales Of Marketable Securities689,630,000—326,723,000
Acquisition Of Property Plant And Equipment22,666,000—176,737,000
Acquisition Of Business———
Other Investing Activities———
Cash From Investing Activities-129,294,000—-96,155,000
Tax Withholding For Share Based Compensation———
Payments Of Dividends———
Issuance Of Common Stock241,388,000——
Repurchase Of Common Stock———
Issuance Of Long Term Debt0——
Repayment Of Long Term Debt———
Other Financing Activities———
Cash From Financing Activities74,006,000—253,053,000
Change In Cash124,264,000—3,008,000
Cash At End Of Period226,548,000—110,891,000
Income Taxes Paid814,000—0
Interest Paid19,000—0
This is a preview of the latest data. Subscribe to access the full data.
Key Metrics
Fiscal Year202520242023
Earnings Per Share-0.01—-1.92
Price To Earnings Ratio-3,449—-13.9948
Earnings Growth Rate——14.9701
Price Earnings To Growth Ratio——-0.9349
Book Value Per Share3.7636—2.69
Price To Book Ratio9.164—9.9887
Ebitda112,472,000—-174,456,000
Enterprise Value4,641,648,420——
Dividend Yield———
Dividend Payout Ratio———
Debt To Equity Ratio0.5469——
Capital Expenditures——192,458,000
Free Cash Flow——-346,348,000
Return On Equity-0.0035—-0.7565
One Year Beta1.76761.56681.3884
Three Year Beta1.58951.60121.544
Five Year Beta1.59821.33941.4494
This is a preview of the latest data. Subscribe to access the full data.
Insider Transactions
Insider NameRelationship To IssuerTransaction DateAmount Of SecuritiesAcquired Or DisposedSecurities Owned Following Transaction
Ferrari MauroDirector2025-11-288,750D68,764
Hamilton James CChief Medical Officer2025-10-0120,000D212,122
Hamilton James CChief Medical Officer2025-09-1215,000D232,122
Hamilton James CChief Medical Officer2025-09-0215,000D247,122
Hamilton James CChief Medical Officer2025-08-159,389D262,122
This is a preview of the latest data. Subscribe to access the full data.
House Trading
Name Of Reporting PersonReport DateStateTransaction TypeTransaction DateOwner TypeAmount
Daniel Goldman2023-02-24NY10Sale2023-01-31—$1,001 - $15,000
This is a preview of the latest data. Subscribe to access the full data.
Institutional Holdings
Investor NamePeriod Of ReportMarket ValueAmount Of SecuritiesPrice Per Security
CANTOR FITZGERALD, L. P.2025-09-30672,55519,50034.49
JPMORGAN CHASE & CO2025-09-3026,754,479775,71734.49
CIBC Private Wealth Group LLC2025-09-3034,4901,00034.49
CAPTRUST FINANCIAL ADVISORS2025-09-30683,66119,82234.49
Advisory Services Network, LLC2025-09-302,6217634.4868
This is a preview of the latest data. Subscribe to access the full data.
Mutual Fund Holdings
Registrant NamePeriod Of ReportFund NameFund SymbolAmount Of UnitsValue In UsdPercentage Value Compared To Assets
PRAXIS FUNDS2025-09-30Praxis Small Cap Index Fund Class IMMSIX4,483154,618.670.0776
PRAXIS FUNDS2025-09-30Praxis Small Cap Index Fund Class AMMSCX4,483154,618.670.0776
RYDEX SERIES FUNDS2025-09-30Class CRYCFX25,732887,496.680.986
RYDEX SERIES FUNDS2025-09-30Class ARYBOX25,732887,496.680.986
RYDEX SERIES FUNDS2025-09-30Class HRYOAX25,732887,496.680.986
This is a preview of the latest data. Subscribe to access the full data.